Skip to content
Comparison

Tirzepatide (Mounjaro/Zepbound) vs Ozempic (Semaglutide)

Tirzepatide (Mounjaro for T2D, Zepbound for obesity) and Ozempic (semaglutide 0.5–2 mg, for T2D) are both once-weekly injectable GLP-1-based medications, but they differ in mechanism, potency, and approved indications. Tirzepatide adds GIP receptor activation to GLP-1 action — a "dual incretin" approach that consistently produces more weight loss and greater A1C reduction than semaglutide at comparable doses. Head-to-head data from SURPASS-2 confirms tirzepatide outperforms semaglutide on both primary endpoints. However, Ozempic has 7+ years of real-world safety data and a proven cardiovascular benefit established in SUSTAIN-6.

4.3(112 ratings)

Quick Answer

Tirzepatide (Mounjaro/Zepbound) outperforms Ozempic on weight loss and A1C reduction in head-to-head trials. SURPASS-2 found tirzepatide reduced A1C ~0.5–1.0% more and produced 2–4 kg more weight loss than semaglutide at all doses compared. Tirzepatide also tends to cause less nausea at equivalent efficacy doses. Ozempic has a longer track record, proven cardiovascular benefit in SUSTAIN-6, and wider T2D formulary coverage. For maximum glycemic/weight efficacy, tirzepatide leads; for patients with established cardiovascular disease, Ozempic's proven CV benefit matters.

Head-to-Head Comparison

CriteriaTirzepatide (Mounjaro/Zepbound)Ozempic (Semaglutide)
Active ingredient & mechanismTirzepatide — dual GIP + GLP-1 receptor agonist ("twincretin")Semaglutide — GLP-1 receptor agonist only
FDA approval yearMounjaro (T2D): May 2022; Zepbound (obesity): Nov 2023; OSA: Dec 2024Ozempic (T2D): Dec 2017; Wegovy (obesity): Jun 2021
Available doses (T2D/obesity)2.5 mg → 5 → 7.5 → 10 → 12.5 → 15 mg weekly0.25 mg → 0.5 → 1.0 → 2.0 mg weekly (Ozempic); 0.25 → 2.4 mg (Wegovy)
A1C reduction (head-to-head, SURPASS-2)~2.0–2.3% reduction at 5–15 mg vs semaglutide 1 mg~1.5% reduction at 1 mg — tirzepatide superior at all doses
Weight loss (head-to-head)~7.6–11.2 kg in SURPASS-2 vs semaglutide~5.7 kg at semaglutide 1 mg in SURPASS-2
Nausea incidence~31% in SURPASS-2 / SURMOUNT-1 (highest dose)~20–25% at Ozempic doses; ~44% at Wegovy 2.4 mg dose
Cardiovascular outcomesSURPASS-CVOT ongoing (no dedicated completed CV outcomes trial for tirzepatide)26% MACE reduction in SUSTAIN-6 (T2D, high CV risk); 20% reduction in SELECT (obesity)
Half-life~5 days~7 days
US list price (2026)~$1,060–$1,200/month (Mounjaro/Zepbound)~$935–$1,000/month (Ozempic)
Oral option availableNo (oral tirzepatide in Phase 3 trials)Rybelsus (oral semaglutide 3–14 mg) for T2D only
Years on market~3 years (Mounjaro since 2022)~7 years (Ozempic since 2017)

When to Choose Each

Choose Tirzepatide (Mounjaro/Zepbound)

Patients needing greater A1C reduction or more weight loss, those who have plateaued on Ozempic, patients with both T2D and obesity who want maximum impact on both endpoints, and anyone with obstructive sleep apnea and obesity (unique Zepbound approval).

Choose Ozempic (Semaglutide)

Patients with established cardiovascular disease seeking the proven 26% MACE reduction from SUSTAIN-6, those who want the longer real-world safety profile, patients preferring oral semaglutide (Rybelsus) for T2D, or those with better insurance coverage for Ozempic.

Verdict

On clinical efficacy measures — A1C reduction and weight loss — tirzepatide outperforms semaglutide (Ozempic) at comparable doses in every head-to-head comparison conducted to date. For patients whose primary goal is greater glycemic control or weight loss, tirzepatide is the superior evidence-based choice. Ozempic retains important advantages: seven-plus years of real-world safety data, dedicated cardiovascular outcomes trial data (SUSTAIN-6 and SELECT), wider formulary coverage for T2D, and an oral formulation option (Rybelsus). For patients with established cardiovascular disease, Ozempic's proven 26% MACE reduction in SUSTAIN-6 and 20% reduction in SELECT are clinically meaningful. The appropriate choice depends on your primary diagnosis, cardiovascular history, efficacy targets, and insurance coverage. Consult your provider.

References

  1. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2) (2021) — PubMed
  2. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1) (2022) — PubMed
  3. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6) (2016) — PubMed
  4. Semaglutide and cardiovascular outcomes in patients with overweight or obesity (SELECT) (2023) — PubMed
  5. GIP and GLP-1 as incretin hormones: lessons from single and dual incretin receptor knockouts in mice (2023) — PubMed
  6. Tirzepatide once weekly for the treatment of obesity in adults with type 2 diabetes (SURMOUNT-2) (2023) — PubMed

Compare Telehealth Providers

Find the right provider for your peptide therapy needs

Hims & Hers

Most Popular
4.3

Starting at $199/mo

Hims & Hers is a leading telehealth platform offering physician-supervised GLP-1 weight loss programs including compounded semaglutide and tirzepatide. Board-certified providers, async or video consults, and medication shipped to your door.

✓Large, established platform with strong physician network
✓Compounded semaglutide available where branded shortages exist
✓Easy async consult — no video call required
✗Does not offer a wide range of peptides beyond GLP-1s
✗Pricing is on the higher end for GLP-1 programs

Henry Meds

Most Peptides
4.2

Starting at $249/mo

Henry Meds is a telehealth provider specializing in hormone optimization and peptide therapy. Beyond GLP-1 weight loss, Henry Meds offers testosterone replacement therapy, growth hormone peptides, and other advanced hormonal protocols managed by licensed physicians.

✓Broadest peptide therapy menu of any major telehealth provider
✓Growth hormone peptides (sermorelin, ipamorelin, CJC-1295) available
✓Repair peptides including BPC-157 and TB-500
✗Higher starting price due to comprehensive programs
✗More complex onboarding including lab work requirements

Ro Body

Best Value
4.1

Starting at $149/mo

Ro Body is a telehealth weight management program powered by GLP-1 medications. Ro connects patients with licensed providers who prescribe compounded semaglutide or branded GLP-1 therapies depending on eligibility, paired with behavioral coaching.

✓Competitive pricing starting at $149/mo
✓Dedicated health coach included in program
✓Strong clinical protocols with lab-work integration
✗Narrower peptide offering — GLP-1s only
✗Video consult required for initial visit

Calibrate

4.0

Starting at $199/mo

Calibrate is a metabolic health company offering a one-year GLP-1 program built around four pillars: food, sleep, exercise, and emotional health. Calibrate works with insurance to cover medication costs and provides extensive behavioral coaching alongside prescriptions.

✓Insurance navigation support for medication coverage
✓Evidence-based one-year program with structured milestones
✓Four-pillar lifestyle coaching (food, sleep, exercise, emotional health)
✗Annual program commitment required
✗Primarily focused on GLP-1s — no broader peptide therapy

Found

3.9

Starting at $129/mo

Found is a weight management telehealth platform that combines GLP-1 medications with behavioral coaching and a supportive community. Found emphasizes a whole-person approach, pairing pharmacological treatment with lifestyle intervention for sustainable results.

✓One of the more affordable monthly program fees
✓Strong community and peer support features
✓Certified health coaches with regular check-ins
✗Medication billed separately from program fee — total cost can be higher
✗Limited peptide variety beyond standard GLP-1s

Sponsored · We may earn a commission. Learn more · Updated February 2026

Hims & HersMost Popular

Hims & Hers is a leading telehealth platform offering physician-supervised GLP-1 weight loss programs including compounded semaglutide and tirzepatide. Board-certified providers, async or video consults, and medication shipped to your door.

From $199/moLearn More →
Henry MedsMost Peptides

Henry Meds is a telehealth provider specializing in hormone optimization and peptide therapy. Beyond GLP-1 weight loss, Henry Meds offers testosterone replacement therapy, growth hormone peptides, and other advanced hormonal protocols managed by licensed physicians.

From $249/moLearn More →
Ro BodyBest Value

Ro Body is a telehealth weight management program powered by GLP-1 medications. Ro connects patients with licensed providers who prescribe compounded semaglutide or branded GLP-1 therapies depending on eligibility, paired with behavioral coaching.

From $149/moLearn More →

Sponsored · Affiliate Disclosure

Frequently Asked Questions

Is tirzepatide stronger than Ozempic?
In head-to-head clinical trials (SURPASS-2), tirzepatide outperformed semaglutide (Ozempic) at all doses tested on both A1C reduction and weight loss. Tirzepatide at 5 mg was superior to semaglutide 1 mg; at 10 mg and 15 mg the advantage grew further. Tirzepatide's dual GIP/GLP-1 mechanism appears to explain this additional efficacy. Whether "stronger" means better for any individual patient depends on their health history, cardiovascular risk, and tolerability. Consult your provider.
Which is better for type 2 diabetes — tirzepatide or Ozempic?
For glycemic efficacy alone, tirzepatide (Mounjaro) reduces A1C more than Ozempic in head-to-head data. For patients with T2D and established cardiovascular disease, Ozempic has the proven cardiovascular benefit from SUSTAIN-6 (26% MACE reduction) that tirzepatide does not yet have from a completed dedicated CV outcomes trial. For most T2D patients without high cardiovascular risk, tirzepatide is generally preferred for superior glycemic and weight outcomes. For those with heart disease, the CV data conversation with your cardiologist is important.
Can I switch from Ozempic to tirzepatide?
Yes, switching is common and generally safe under physician supervision. Many patients who plateau on Ozempic transition to tirzepatide and experience renewed weight loss and A1C improvement. A typical approach is to stop Ozempic and start tirzepatide at 2.5 mg, then titrate up as tolerated. Because both drugs affect GI motility, allow some time for adjustment. Always coordinate medication changes with your prescribing provider.
Why does Ozempic cost less than tirzepatide?
At 2026 US list prices, Ozempic is slightly less expensive than Mounjaro/Zepbound (~$935–$1,000 vs ~$1,060–$1,200/month). Ozempic has been on the market longer, faces more formulary competition, and Novo Nordisk has adjusted pricing. Both have manufacturer savings programs for commercially insured patients. Compounded versions of both are available from 503B facilities at lower cost where legal. Insurance coverage and prior authorization requirements significantly affect actual patient out-of-pocket cost.
Does Ozempic have an oral version?
Yes — Rybelsus (oral semaglutide 3 mg, 7 mg, 14 mg daily) is FDA-approved for type 2 diabetes, though not for weight loss. Oral semaglutide produces less weight loss than injectable Wegovy (2.4 mg weekly) due to lower bioavailability and the lower doses used orally. Tirzepatide does not currently have an approved oral formulation, though Phase 3 trials of oral tirzepatide are underway as of 2026. If avoiding injections is a priority, ask your provider about Rybelsus.

Explore next